BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The most effective method to Succeed in Your Web based Advertising Degree: Procedures for Progress - 2In the background: Visiting Notable Film Areas All over the Planet
- 3Spots to Go Hang Floating
- 4Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- 5UN mission says no evidence Hezbollah rearming in southern Lebanon
- What to know about the hepatitis B shot — and why Trump officials are targeting it
- Germany paves the way for tighter EU asylum rules
- Public Parks in the USA
- Which camera do you believe is great for first-time clients? !
- Could the Star of Bethlehem have actually been a comet?
- Native Americans had dice and games of probability long before other cultures, study finds
- Scientists captured female sperm whales on video working together during a birth to protect the calf
- Manual for Purchasing a Modest Jeep Wrangler for Seniors
- Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
